ProShare Advisors’s SpringWorks Therapeutics SWTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-21,336
| Closed | -$1M | – | 2113 |
|
|
2025
Q2 | $1M | Buy |
21,336
+3,074
| +17% | +$137K | ﹤0.01% | 818 |
|
|
2025
Q1 | $806K | Sell |
18,262
-4,621
| -20% | -$213K | ﹤0.01% | 876 |
|
|
2024
Q4 | $827K | Buy |
22,883
+5,503
| +32% | +$192K | ﹤0.01% | 999 |
|
|
2024
Q3 | $557K | Buy |
17,380
+3,631
| +26% | +$136K | ﹤0.01% | 1079 |
|
|
2024
Q2 | $518K | Sell |
13,749
-3,724
| -21% | -$157K | ﹤0.01% | 953 |
|
|
2024
Q1 | $860K | Buy |
17,473
+2,368
| +16% | +$109K | ﹤0.01% | 833 |
|
|
2023
Q4 | $551K | Buy |
15,105
+3,440
| +29% | +$89.8K | ﹤0.01% | 985 |
|
|
2023
Q3 | $270K | Buy |
11,665
+40
| +0.3% | +$1.09K | ﹤0.01% | 1262 |
|
|
2023
Q2 | $305K | Buy |
11,625
+3,054
| +36% | +$80.3K | ﹤0.01% | 1262 |
|
|
2023
Q1 | $221K | Sell |
8,571
-1,223
| -12% | -$35.7K | ﹤0.01% | 1395 |
|
|
2022
Q4 | $255K | Buy |
9,794
+1,817
| +23% | +$44.8K | ﹤0.01% | 1329 |
|
|
2022
Q3 | $227K | Buy |
+7,977
| New | +$229K | ﹤0.01% | 1325 |
|
|
2022
Q2 | – | Sell |
-10,582
| Closed | -$597K | – | 2100 |
|
|
2022
Q1 | $597K | Sell |
10,582
-2,732
| -21% | -$156K | ﹤0.01% | 1170 |
|
|
2021
Q4 | $826K | Sell |
13,314
-923
| -6% | -$61.1K | ﹤0.01% | 1151 |
|
|
2021
Q3 | $903K | Sell |
14,237
-2,153
| -13% | -$166K | ﹤0.01% | 938 |
|
|
2021
Q2 | $1.35M | Buy |
16,390
+3,192
| +24% | +$242K | ﹤0.01% | 869 |
|
|
2021
Q1 | $971K | Buy |
13,198
+347
| +3% | +$27.2K | ﹤0.01% | 1001 |
|
|
2020
Q4 | $932K | Buy |
+12,851
| New | +$827K | ﹤0.01% | 911 |
|
Other funds holding SWTX
ProShare Advisors's SWTX Position: Q3 2025 in Review
ProShare Advisors sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 21,336 shares — an estimated $1M sold.
ProShare Advisors first reported a position in SWTX in Q4 2020 and held it in 18 quarters. The position peaked at $1.35M in Q2 2021. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.
- ProShare Advisors reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
- ProShare Advisors sold 21,336 SpringWorks Therapeutics shares in Q3 2025, an estimated $1M.
- ProShare Advisors first reported a position in SpringWorks Therapeutics in Q4 2020 and held it in 18 quarters.
- ProShare Advisors's SpringWorks Therapeutics position peaked at $1.35M in Q2 2021.
- 3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.
Based on ProShare Advisors's 13F filing for Q3 2025, filed 6 Nov 2025.